GLP-1 in perimenopause: does it work, and does it mix with your hormones?

Do GLP-1s actually work in perimenopause, at your age?

They do. The typical person in the trials that won FDA approval was a woman in her mid-40s, which is the heart of perimenopause.

GLP-1 drugs copy a gut hormone that tells your brain you are full and slows how fast food leaves your stomach. Semaglutide is the drug in Wegovy and Ozempic. Tirzepatide, in Zepbound and Mounjaro, also acts on a second gut hormone called GIP.

In the STEP 1 trial of semaglutide, 1,961 adults without diabetes were randomly assigned to the drug or a placebo, a dummy shot. About three in four were women, and their average age was 46.

After 68 weeks, people on semaglutide had lost 14.9 percent of their body weight on average. The placebo group, which got the same diet and activity counseling, lost 2.4 percent.

The SURMOUNT-1 trial of tirzepatide enrolled 2,539 adults. About two in three were women, with an average age of about 45.

At the highest dose, people on tirzepatide lost 20.9 percent of their weight over 72 weeks. Those on placebo lost 3.1 percent.

Each result belongs to its own drug and trial. The two numbers came from different studies, so they can't be lined up as a fair contest. A direct comparison comes further down.

Here is the gap. Neither trial reported results by menopause stage, so nobody knows how many women were still cycling. The evidence fits your age group without testing perimenopause as such.

Real-world data point the same way. A Mayo Clinic review of 1,039 tirzepatide users who stayed on it for at least a year found that women lost more than men. Younger patients lost a little more than those over 60, but age stopped mattering once other factors were accounted for.

So your age is not the obstacle. What decides the result is mostly staying on the drug, which the last section of this guide covers.

Can you take a GLP-1 with HRT, and does it change how your hormones work?

Yes, you can take both. Neither the Wegovy nor the Zepbound label lists menopause hormone therapy, often called HRT, among its drug interactions.

The real question is your stomach, not your hormones. GLP-1s slow gastric emptying, the speed at which food and pills move from your stomach into your gut. The labels warn that this can change how well other oral medicines are absorbed.

Oral estradiol and oral progesterone

No study has measured oral estradiol or oral micronized progesterone, the body-identical capsule, alongside a GLP-1. What we do have is a test with the birth control pill and tirzepatide.

After a single tirzepatide dose, peak blood levels of the pill's hormones fell by more than half. Total exposure over time dropped by about a fifth, according to the Zepbound label.

The Mounjaro label adds that this slowing is strongest after the first dose and fades over time. HRT doses are not birth control, so the stakes differ. Still, the same slowing can affect any hormone you swallow, even though no study has measured it for HRT.

If hot flashes or night sweats creep back in the weeks after you start or step up a dose, slower absorption is one possible reason. No study has confirmed it, and it is not a reason to stop either drug.

If you take oral progesterone to protect the lining of your uterus while on estrogen, taking it steadily matters. A 2026 review in Maturitas found no data on tirzepatide with the progestogens used in HRT. It calls an effect possible but unproven.

Patches, gels and rings skip the gut

Estrogen patches, gels, sprays and vaginal rings are absorbed through the skin or the vaginal wall. They never pass through the stomach.

The Mounjaro label says birth control that is not taken by mouth should not be affected. The same logic suggests an estrogen patch sidesteps the issue, though no study has tested HRT directly.

Does HRT make a GLP-1 work better?

Two small Mayo Clinic studies hint at it. Both were retrospective, meaning researchers looked back at existing patient records rather than running a trial. Our guide to HRT and weight loss puts these studies in context.

• Semaglutide. A 2024 study in the journal Menopause looked at 106 postmenopausal women, 16 of them on hormone therapy. At 12 months, hormone users had lost about 16 percent of their weight, against about 12 percent for non-users.
• Tirzepatide. A Mayo Clinic records study compared 40 postmenopausal women on hormone therapy with 80 who were not, all taking tirzepatide. In a 2025 congress abstract, which was not peer reviewed, hormone users lost about 17 percent of their weight over a median of 18 months. Women not on hormone therapy lost about 14 percent.

Both studies were in women already past menopause, not in perimenopause. Women who use hormone therapy may also differ from non-users in health, income or access to care.

A 2026 clinical review in Obesity Pillars concludes that hormone therapy should not be prescribed for weight loss. A 2026 Spanish Menopause Society position statement calls the semaglutide link hypothesis-generating and advises against starting hormones only to boost a GLP-1.

The broader question of combining the two after menopause has its own page, GLP-1 for menopause weight gain. If you worry that HRT itself adds pounds, our guide on HRT and weight gain in perimenopause covers what the trials found.

Still on the pill? Tirzepatide can make it less reliable

This is the most perimenopause-specific issue on the page, and it is easy to miss. Many women in their 40s still use the pill, and many still ovulate some months.

The Mounjaro and Zepbound labels, both revised in 2026, say tirzepatide may reduce how well oral hormonal contraceptives work. The cause is the slower stomach emptying described above.

Their advice has two options. You can switch to a method that is not taken by mouth. Or you can add a barrier method, such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase.

The window restarts with every step up because each higher dose slows the stomach again. In practice, that can mean several backup windows during the first months.

Foundayo, Lilly's once-daily GLP-1 pill approved in April 2026, carries similar advice. Its label asks for a non-oral method or a barrier method for 30 days after starting and after each dose increase.

Semaglutide is a separate case

Novo Nordisk tested semaglutide with a combined pill containing ethinyl estradiol and levonorgestrel. The Ozempic and Wegovy labels report no clinically relevant interaction, and they carry no backup-method instruction.

That finding applies to semaglutide only. It does not carry over to tirzepatide or Foundayo, whose labels carry the backup-method advice.

Minipills, HRT and what counts as non-oral

Progestin-only pills, often called minipills, are not carved out. The tirzepatide label speaks of oral hormonal contraceptives in general, even though its test used a combined pill.

HRT is not birth control. The estrogen and progesterone doses used for symptoms are not designed to stop ovulation.

Non-oral methods include the hormonal IUD, the implant, the vaginal ring, the skin patch and the shot. As noted above, the Mounjaro label says these should not be affected. Not every method suits every woman over 40, and our guide to perimenopause birth control walks through the options.

One more point applies to every GLP-1. Nausea, vomiting and diarrhea are common early on, and CDC birth control guidance has separate backup rules for vomiting or severe diarrhea while on the pill.

Can you still get pregnant on semaglutide or tirzepatide in perimenopause?

Yes. Irregular periods do not mean you have stopped ovulating.

The CDC's 2024 contraception guidance says women over 44 still need birth control if they want to avoid pregnancy. It states that no reliable lab test confirms the end of fertility. It also says an FSH blood test, a common hormone check, might not be accurate for this.

The same CDC document notes that ACOG and The Menopause Society recommend birth control until menopause or age 50–55.

You may have seen stories about Ozempic babies, surprise pregnancies on GLP-1 drugs. These are news and social media reports, not trial findings, and no study has measured how often they happen.

Medical reviews propose a plausible reason. Losing weight can restart ovulation in women who were not ovulating regularly, a pattern best studied in polycystic ovary syndrome, or PCOS. With tirzepatide or Foundayo, a less reliable pill can add to that.

Birth control is often not discussed at the start. In Australian general practice records, fewer than one in four women of reproductive age had contraception recorded when a GLP-1 was prescribed.

What the labels say about pregnancy

• Wegovy. Stop at least 2 months before a planned pregnancy, because semaglutide stays in the body for weeks.
• Zepbound. Stop when a pregnancy is recognized. The label says weight loss offers no benefit during pregnancy.
• Registries. Both makers run pregnancy registries that track outcomes in women exposed to their drugs.

The CDC also notes that pregnancies later in reproductive life carry higher risks for both mother and baby. Our guide to pregnancy in perimenopause covers the odds, the signs and the tests.

Do you qualify, and will insurance cover a GLP-1 for perimenopause weight loss?

Perimenopause itself is not a reason any GLP-1 is approved. What counts is your weight and your health conditions.

Wegovy, Zepbound and Foundayo are approved for adults with obesity, or with overweight plus at least one weight-related condition. Common examples are high blood pressure, high cholesterol and type 2 diabetes.

In the trials, that meant a body mass index, or BMI, of 30 or more. BMI is a score that compares your weight with your height. People with a BMI of 27 or more also qualified if they had a weight-related condition.

Other approved uses that can matter for coverage

• Wegovy and heart disease. It is approved to lower the risk of heart attack, stroke and heart-related death in adults with established heart disease and obesity or overweight.
• Wegovy and fatty liver. The injection is approved for MASH, a fatty liver disease, when it has caused moderate to advanced scarring. This approval is accelerated, meaning it can depend on confirmation in further trials.
• Zepbound and sleep apnea. It is approved for moderate to severe obstructive sleep apnea, where the airway keeps closing during sleep, in adults with obesity.
• Ozempic and Mounjaro. Both are approved for type 2 diabetes. So is the Ozempic pill, the tablet formerly sold only as Rybelsus. Using them for weight alone is off-label, meaning outside the approved use.

Insurance coverage for weight management varies widely, and some plans exclude it entirely. A covered diagnosis such as heart disease or sleep apnea can change the answer. Many plans also require prior authorization, a step where the insurer must approve the drug before it pays.

If your plan says no, self-pay programs from the makers and lower-cost compounded versions are the usual next steps. Compounded drugs are made by pharmacies and are not FDA approved, and our compounded GLP-1 guide compares those providers.

Semaglutide or tirzepatide: which suits a perimenopausal woman?

On weight alone, tirzepatide came out ahead in the one head-to-head trial. In SURMOUNT-5, adults with obesity but without diabetes took one drug or the other for 72 weeks. There was no placebo group.

People on tirzepatide lost 20.2 percent of their body weight on average. People on semaglutide lost 13.7 percent.

Perimenopause adds a factor most comparisons skip. If you rely on the pill and don't want to change it, semaglutide avoids the backup windows that tirzepatide requires. If you have a hormonal IUD or an implant, that difference disappears.

Format is the other choice. Most options are weekly injections. The Wegovy pill, a daily semaglutide tablet, was approved for weight in December 2025. Foundayo is a daily pill of a different molecule, orforglipron, and it carries the same pill warning as tirzepatide.

Our pages on semaglutide vs tirzepatide and GLP-1 pills vs injections compare side effects, prices and convenience in detail.

Will a GLP-1 change your periods or your hot flashes?

Periods

The Wegovy and Zepbound labels say nothing about menstrual cycles. The trials did not track periods as an outcome.

In perimenopause, two forces can act at once. Your cycles are already shifting, and weight loss can bring back ovulation in some women. The result is often less predictable, not more.

Bleeding that is much heavier or longer than your usual deserves a check, whatever drug you take. Our guides to heavy periods and erratic periods explain what is typical and what is not.

Hot flashes

A GLP-1 is not a hot flash treatment. No GLP-1 is FDA approved for hot flashes or night sweats.

Weight loss itself is a different matter. The Menopause Society's 2023 nonhormone position statement lists weight loss among recommended options for hot flashes. It rates the evidence Level II to III, meaning limited studies and expert consensus rather than strong trials.

The same statement calls hormone therapy the most effective treatment for hot flashes. Our perimenopause hot flashes guide covers both routes.

HRT first or GLP-1 first?

Start with whatever bothers you most. A short rule of thumb helps.

• Symptoms come first. If hot flashes, night sweats or broken sleep run your days, HRT targets them directly. A GLP-1 does not.
• Weight and health risk come first. If you meet the BMI rules, especially with a condition such as high blood pressure or sleep apnea, a GLP-1 is the drug aimed at that. HRT is not a weight-loss drug.
• Both weigh on you. The two can run together. Starting one at a time makes it easier to tell which drug is behind a new side effect.

Our HRT vs Ozempic page sets the prices side by side and gives a verdict. For the full order of weight options in perimenopause, from lifestyle to older drugs, see perimenopause weight loss medication.

Muscle, bone and hair at 40+: what to watch for on a GLP-1

Women already lose muscle and bone with age, so four label and trial findings deserve a look. Each comes from one drug's data and should not be applied to the others.

• Lean mass with tirzepatide. In a body-scan sub-study of SURMOUNT-1, about a quarter of the weight lost was lean mass. The share was the same on placebo. Lean mass includes muscle, organs and water, not muscle alone.
• Lean mass with semaglutide. A STEP 1 body-scan sub-study, reported as a 2021 congress abstract, scanned 140 people, 95 on semaglutide and 45 on placebo. On semaglutide, lean mass fell about 10 percent and fat mass about 19 percent. The placebo group lost 3.6 percent of its weight, and the abstract reports no major change in its body composition.
• Bone with semaglutide. SELECT, the heart outcomes trial on the Wegovy label, enrolled adults with heart disease and overweight or obesity. Hip and pelvis fractures occurred in 1 percent of women on Wegovy, against 0.2 percent of women on placebo.
• Hair with tirzepatide. The Zepbound label reports hair loss in 7.1 percent of women on the drug, against 1.3 percent of women on placebo. The label links it to weight reduction.

You may read that HRT protects muscle during GLP-1 weight loss. No study has tested that. A 2006 meta-analysis often cited on HRT and body shape found less belly fat and better insulin response, and it did not report on muscle.

Protein, strength training and the scan data are covered in our guide to GLP-1 muscle loss in perimenopause.

How long do you stay on it, through menopause and after?

Plan for the long term, because the weight tends to return when the drug stops.

In the STEP 1 extension, 327 people were followed for a year after stopping semaglutide. They regained about two-thirds of the weight they had lost.

Two years from the start, the former semaglutide group sat 5.6 percent below their starting weight. The former placebo group sat 0.1 percent below theirs.

SURMOUNT-4 tested stopping tirzepatide. Everyone first took it for 36 weeks and lost 20.9 percent of their weight on average.

Then half were switched to placebo, and over the next year they regained 14 percent of their weight. Those who stayed on tirzepatide lost a further 5.5 percent.

The menopause transition can last several years, and weight pressure does not end at your last period. Our perimenopause weight gain guide explains why that pressure builds. A GLP-1 started in perimenopause is best treated as a plan that may run well past menopause, not a short course.